Member Info for Doc.Daneeka

I think people can see the difference, and I was surprised at the vitriol following today's post - but then I looked at the twitter activity for Feb. Some of which was greeted with similar abuse.
Feb 1 & 2 - almost identical tweets linking to Ep 2 of the podcast
Feb 3rd "Happy US National Women Physicians Day ..."
Feb 6th "Recognising SNG women in Science" Donna Davies
Feb 7th "Recognising SNG women in Science" Victoria Tear
Feb 8th "Recognising SNG women in Science" Jody Brookes
Feb 9th "Recognising SNG women in Science" Brooke Clarke
Feb 11th "Today, #Synairgen celebrates the International Day of Women and Girls in Science " with pics of the 4 ladies already tweeted about.
So a whole week of women in Science - 5 touchy feely tweets that should have begun and ended with Donna Davies.
I'd never be critical directly to the company of such activity but but twitter is a brutal place where anonymity emboldens those with a particularly harsh perspective. For a firm that hasn't tweeted anything substantive since the deep dive data was released you can see that a lot of investors are losing patience when an entire week is devoted to this. And predict that every non-business post from now on will attract the same rancour. A few troublemakers maybe - but hardly any likes or word of support tells the story. And how Brooke Clarke gets a mention while Maud is left polishing her teapot is anyone's guess.

They've been warning about it for a long time and obviously didn't want to do it - but it's all smoke and mirrors with the Govt now and if they can't see that a company of the size and value of AZ needs incentives to stay here then we really are doomed.

Anyone who listened to R4's Today would have heard the complete opposite to this story of positiivity. AZ deciding to open a new facillity in Ireland instead of here because 12.5% corporate tax rate compared to 25% (in April) an end to fuel support and various other breaks that Ireland gives compared to this knackered country. Also mentioned the lack of availability of patients for trialing because the NHS is still overwhelmed and how much it costs pharma to operate here, compared to the billions on offer for overseas pharmas in the States and a similar scheme that's about to launch in the EU. Identifying and hopefully targeting the US is the one solid good decision Synairgen has made since SGO16

this is the NIH news release from Feb 2
https://www.nih.gov/news-events/news-releases/lessons-learned-nih-led-research-response-covid-19

with respect chaps - you can't post at the weekend to tell someone else off for posting at the weekend

Someone must have posted this already I'm sure - but if not here's a comprehensive review of what NIH has been doing since the pandemic started. It is a story of huge success and speed - covering vaxes as well as therapeutics and giving credit to the UK for the Dexa work which was possible because of the structure and unity of the NHS.

We are not mentioned of course but our shadow is there. 29 candidates selected so far - 6 of which were successfully trialed and approved and the 19 of which failed. I guess SNG001, SAB 185 & Brii 196 &198 - all passing the ACTIV 2 P2 but left in limbo as Omicron made the P3 investigations futile - should account for 3 of them. Not sure what the last might be.
Lessons learned include international cooperation - imagination in trial design and speed in protocol design and approvals or rejections.

" This partnership with other federal agencies, 20 companies, and several nonprofit organizations involved more than 100 scientists from all sectors in a team-science approach to achieve rapid testing of potential treatments and mount the largest, most comprehensive drug repurposing effort to date. This included a highly efficient, rigorous process for soliciting candidate compounds; assembling uniform dossiers of relevant data and conducting a systematic evaluation of more than 800 agents with various mechanisms of action; and selecting 34 agents for inclusion in ACTIV master protocols.
"Managed by a mix of academic experts and the staff at the Foundation for the NIH (FNIH), and funded in part through OWS, ACTIV has so far completed testing of 29 candidates, enrolling more than 22,000 participants in more than 40 substudies. Six of those candidates have shown compelling evidence of benefit and are now approved for clinical use. Nineteen (including ivermectin) have been shown definitively to be ineffective, which is valuable knowledge to reduce misinformation and focus on providing effective treatments to appropriate patients.

https://www.science.org/doi/10.1126/science.adf5167

"Synairgen can collaborate with BP on trials, become a royalty engine through franchising, and retrench themselves as an operation into R&D to feed that commercial model indefinitely. "

We've had some funny stuff on here but this is priceless. Every syllable drippingly rich with unintended or maybe intended irony. Is "Royalty engine" funnier than "retrench themselves as an operation into R&D to feed that commercial model indefinitely."

I dunno. What I do know is that you don't believe a word of it. Not a single word.

Monte - take the old girl out. She deserves it

82 days - apologies - you're right - snail's pace

If you think we can find the funding for a 1k confirmatory trial - find all the new trial sites and deliver it more efficiciently alone than with NIH assistance you're madder than I thought. Without even considering the dilution required to fund a trial that might cost more than twice the value of the company ?
Mani and Tommy tried to convince us that the delay with out Activ results and the political shenanigans that plague US trialing meant that NIH was slow and not to be trusted, but those of us who've been around since the start know the truth, which is that NIH has the greatest trialing network on the planet and that the speedy work it did in Covid provided a new template for the way clinical trials should be run in the future. Plenty of drugs were trialed and authorised at warp speed. Bamlanivimab for example - the first Activ drug - went from FPD on Aug 19th 2020 to EUA on November 9th 2020. 80 days. And passed P2 and 3. 82 days !! The fact that the EUA was withdrawn a few months later as a new variant arrived is neither here nor there. They did it and then went on to repeat the feat with many other drugs.
We screwed up Sprinter on our own. Too small a trial size - too many sites in disparate jurisdictions, a faliure to spot a change in SOC that was already in place as the trial was being designed and duff endpoints.
I'd much rather hand it over to NIH and its huge network of trialing hospitals than risk another heroic failure.

If we don't get Strive it'll be because they don't want us - and if that happens we'll have lost the last fast chance of rescuing our lost investments . SNG will survive of course - Synairgen itself may survive, but it'll be the slow boat to China for all of us

the job description was so broad and extensive - felt like it was too much for one person, so not surprising.
It's STRIVE though. Guaranteed. 100% (Sorry - must be Friday ! )

"Out of interest, many of the top 10 pharma hubs are located on the East Coast Corridor in the US, e.g.:
Boston-Cambridge
New York
Maryland/DC
Philly
Raleigh-Durham, NC "

And of course NIH and FDA are both in Maryland

Nice post Trinityman - summarising, as ever, the key elements of the current debate. Your example of Angle PLC is particularly apposite and backs up my long held and argued point that our path to becoming a multi virus therapeutic will begin with one major trial - and clearly that trial ought still to be for Covid -19, the virus we have most evidence for. Even the most ardent supporters of the oft mooted trial to test SNG simultaneously against multiple viruses, have to admit that such a trial has never happened before.
Still hopeful for Strive above all else - but fearful of the looming anniversary.

I don't think they knew what to do with it. Stacey said something along these lines in the Grand Rounds presentations but i couldn't find it when i skimmed through a while after it was produced. That there were certain agents that they hadn't made a decision on for one reason or another
At that stage we'd arrived at the wedding - suited and booted, and after sitting down in the cold empty church for half an hour the vicar popped his head through the doorr to say there'd been a falling out and it was all off. And would we mind awfully pi.ssing orf.
We suffered the same fate as my namesake in the great novel - who, though still alive, was believed to have been killed in a plane crash and thereafter wiped from all records and henceforth invisible to the rest of the characters in the book. "I'm right here " he'd say - but to no avail. He was officially dead.

Might just be that some of the turbo juice they were all running on from early 2020 until Omicron calmed everything down in the middle of last year has flushed out of the big agency system and they're gradually returning to the slow and laborious habits of old - where different agencies might take weeks and months to do things that can actually be done in days and weeks.

Do you mean AZ and Sanofi's nirsevimab Elsol ?

The Vax megasaurses have never stopped working on other things ( and on other Covid therapeutics as well some of them) but they all understand that the Covid bonanza is almost at its end, and they're all investing much of the windfall ( when I say much - i mean billions) into other product developments and growing the broad pipeline. Covid is not a major focus now though - or even a minor one. They've made their updated vaxes and are making nasal vaxes too and mRNA is being developed in dozens of different directions and they know the last 3 years will never be equalled. ( Pfizer alone made over $90 Billion from its vax and Paxlovid combined over the last 2 years )
Even more galling for little old SNG that nobody (so far at least) has decided to take the tiny punt that would be needed to discover whether it really is what quite a lot of data and RM & SSH say it is - a possible game changing broad spectrum etc etc for every single respiratory virus. This has been my big concern since Sprinter ran aground.
Where are they and why haven't they come for it ?

And I'm cynical about pandemic preparedness too. 2 years ago thhis board was full of " experts" quoting billions and billions in stockpiling sales country by country and announcing loudly that bthe world would never allow the same thing to hapemn again - and yet we can see already that the world is perfectly capable of letting it all go tits up again. The BPs in particular far prefer a crisis and the top dollar they can charge when there's nothing on the shelves. When they start on PP inititiatives the intentions are tremendous because the bodybag images are fresh in the mind but a couple of years down the track when deaths have fallen to almost nothing and other big issues are taking the headlines the report lands on a back office desk and is quietly filed away. We conducted our own worst case scenario study for a Sars lioke pandemic in 2016 (from memory I think) and it was completely ignored. It's really the same as the inquiries that take place after every disaster - only for the exact same disasters to occur again a year or 2 later. You'd hope that in the higher echelons - as if that means anything woth the current Govt we have - Covid might be seen in a different light - but away from boards like this the vast majority of people never give it the smallest thought. Like the lingering tendrils of terror that swirl around in your head when you wake after a nightmare - but by the time breakfast is on the table have gone entirely.

Strange days indeed ( most peculiar mama)

The old NDA get out. I could tell you but i'd have to kill you.....
Theodora Harold left because Crescendo was taking off in a major way. JV with Biontech announed just before Sprinter crashed. She's far busy now with multiple T-cell cancer drugs in development to give any of her time to Synairgen.

He's constantly reposting the same stuff and you're all constantly joining in the conversation. An LTH with this level of specific expertise who's said zero until a week ago. It's pure nonsense.

Nothing will happen to our Sp without news of a trial and we all know this. And even if his Spac lads consortium do believe they know more about the drug's potential than all the Big Pharma M&A teams put together - they'd still wait until Feb 21st and exercise the master plan then.

"All just speculation in the current news vacuum! DYOR! " ffs. Mani's spaccy big brother come to plague us with his junk.

please don't ask him to repeat it Fruits. For goodness sake - it's the biggest cobblers we've ever had on this board and we've had plenty in the last 3 years. His original explanation was guff along the lines of $1b being pocket change in Spacland, witt examples that were utterly irrelevant to our current position.
We showed him the door pretty conclusively yesterday - let's not ask him back in for another day of clever sh.ite.

well done Fruits - nice to be in the conversation anyway.
Also interesting that whilst all 3 vax developers (GSK Pfizer and Moderna) are making older/vulnerable patient vaxes, Pfizer is also making a maternal vaccine to protect babies and young children, via the pregnabt mum. It's a cool idea and already in use for other conditions inc flu. 0-5yr olds account for 100-300 deaths annually in the States - with 6,000-10,000 deaths among adults 65 years and older.

Will also be interesting to see if the immunity is lifelong ( as with pneumonia when vaxed before 65 ) or more like the current C-19 viruses with diminishing protection overr time. Will Moderna's protection flush away as the nRNA vaxes do eventually ?

If it's a one shot job you could imagine a combination shot with the flu jab for older or vulnerable adults. Still leaving plenty of market for whatever can help in the hospitals of course - as many just don't get jabbed no matter what their underlying conditions - but it's to be celebrated that 60 years of research has led suddenly to 3 vaxes which might all be authorised in a few months.

I'm taking a positive signal from this Guardian piece

https://www.theguardian.com/science/2023/jan/31/gene-editing-company-hopes-to-bring-dodo-back-to-life